Current evidence, including magnetic resonance imaging studies, suggests that skeletal muscle alterations resulting from GLP-1 RA-induced weight loss, such as enhanced insulin sensitivity and reduced muscle fat infiltration, are adaptive, thereby improving muscle quality despite concurrent reductions in lean mass [112]
The improvement in ESS and AHI caused by GLP-1 RA is correlated with weight loss, BMI, and reduced waist circumference [45, 49, 82]
Likewise, production of Semaglutide generics is not expected in Europe till 2031-2032 due to extended patent protection
CBO projects that legislation repealing the prohibition would increase drug spending by $38 billion, with offsetting health savings of $3 billion, over the 2026-2034 period
More Study Is Still Needed Even before research on alternative dosing schedules emerged, some clinicians were already experimenting with off-label adjustments to injection frequency
The hormonal imbalances that come with PCOS can further complicate this process
